Array anti-cancer drug falling short
BOULDER – Results of a study on the effectiveness of an anti-cancer drug developed by Array BioPharma Inc. demonstrated an increase in survival rates when combined with another drug, but the results did not reach statistical significance, according to the Boulder-based bioscience company.
The Phase 2 study, conducted by AstraZeneca, demonstrated an increase in survival among 87 patients taking Array’s selumetinib in combination with docetaxel versus docetaxel alone. The patients were prospectively selected with KRAS-mutant, locally advanced or metastatic nonsmall-cell lung cancer.
AstraZeneca is also completing a Phase 2 trial with selumetinib in combination with dacarbazine compared with dacarbazine alone as first-line treatment of patients with melanoma whose tumors harbor BRAF mutations.
SPONSORED CONTENT
Water Wars: Thornton’s struggle and triumph in obtaining Pipeline Permits
Lyons Gaddis understands the complexities and challenges of water and real estate law. This case illustrates an important principle of building water projects: “It never gets easier.”
There are more than 45 on-going or completed Phase 1 or 2 trials with selumetinib.
BOULDER – Results of a study on the effectiveness of an anti-cancer drug developed by Array BioPharma Inc. demonstrated an increase in survival rates when combined with another drug, but the results did not reach statistical significance, according to the Boulder-based bioscience company.
The Phase 2 study, conducted by AstraZeneca, demonstrated an increase in survival among 87 patients taking Array’s selumetinib in combination with docetaxel versus docetaxel alone. The patients were prospectively selected with KRAS-mutant, locally advanced or metastatic nonsmall-cell lung cancer.
AstraZeneca is also completing a Phase 2 trial with selumetinib in combination with dacarbazine compared with dacarbazine alone as first-line…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!